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Abstract: Vascular  endothelial  growth  factor  A  (VEGF-­‐‑A)  signaling  is  essential  for  physiological  8 
and  pathological  angiogenesis.  Alternative  splicing  of  the  VEGF-­‐‑A  pre-­‐‑mRNA  gives  rise  to  a  pro-­‐‑9 
angiogenic   family  of   isoforms  with  a  differing  number  of  amino  acids   (VEGF-­‐‑Axxxa),  as  well  as  a  10 
family   of   isoforms   with   anti-­‐‑angiogenic   properties   (VEGF-­‐‑Axxxb).      The   biological   functions   of  11 
VEGF-­‐‑A  proteins  are  mediated  by  a  family  of  cognate  protein  tyrosine  kinase  receptors,  known  as  12 
the  VEGF  receptors  (VEGFRs).  VEGF-­‐‑A  binds  to  both  VEGFR-­‐‑1,  largely  suggested  to  function  as  a  13 
decoy  receptor,  and  VEGFR-­‐‑2,   the  predominant  signaling  receptor.  Both  VEGFR-­‐‑1  and  VEGFR-­‐‑2  14 
can  also  be  alternatively  spliced  to  generate  soluble  isoforms  (sVEGFR-­‐‑1/sVEGFR-­‐‑2).  The  disruption  15 
of  the  splicing  of  just  one  of  these  genes  can  result  in  changes  to  the  entire  VEGF-­‐‑A/VEGFR  signaling  16 
axis,   such  as   the   increase   in  VEGF-­‐‑A165a   relative   to  VEGF-­‐‑A165b   resulting   in   increased  VEGFR-­‐‑2  17 
signaling  and  aberrant  angiogenesis  in  cancer.  Research  into  this  signaling  axis  has  recently  focused  18 
on  manipulating  the  splicing  of  these  genes  as  a  potential  therapeutic  avenue  in  disease.  Therefore,  19 
further   research   into   understanding   the  mechanisms  by  which   the   splicing   of  VEGF-­‐‑A/VEGFR-­‐‑20 
1/VEGFR-­‐‑2  is  regulated  will  help  in  the  development  of  drugs  aimed  at  manipulating  splicing  or  21 
inhibiting  specific  splice  isoforms  in  a  therapeutic  manner.  22 
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Introduction 25 
Angiogenesis comprises the formation and maintenance of blood vessels. A variety of signaling 26 
molecules are involved in the regulation of angiogenesis, including vascular endothelial growth factor 27 
(VEGF), which is essential both for physiological and pathological angiogenesis [1]. The biological 28 
functions of VEGF proteins are mediated by a family of cognate protein tyrosine kinase receptors, 29 
known as the VEGF receptors (VEGFRs) [2]. Activation of the VEGF pathway has been implicated 30 
in a large number of disease processes ranging from cancer to autoimmunity.  31 
There are several VEGF proteins; VEGF-A binds to and signals through VEGFR-1 (Flt-1) and 32 
VEGFR-2 (KDR/Flk-1), VEGF-B signals solely through VEGFR-1, and VEGF-C and VEGF-D have 33 
a high affinity to VEGFR-3 (Flt-4) [1,2]. In addition, there are two neuropilin receptors, which are 34 
transmembrane glycoproteins, that function in the VEGF-VEGFR axis [2]; neuropilin-1 (NRP-1), a 35 
non-kinase co-receptor for VEGFR-2, functions to enhance the binding and signaling of certain 36 
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isoforms of VEGF-A. NRP-2, on the other hand, is a non-kinase co-receptor for VEGFR-3. Since 37 
VEGFR-1 and VEGFR-2 are the receptor tyrosine kinases specific for VEGF-A, this review will 38 
focus on the splice variants of these two receptors only. 39 
 40 
VEGFR Splice Variants and Functions 41 
VEGF-A binds to two tyrosine kinase VEGFRs, VEGFR-1 and VEGFR-2. There are several isoforms 42 
of these VEGFRs that arise as a result of alternative splicing of the VEGFR pre-mRNA, which can 43 
alter the protein function, as detailed below (Figure 1). Both VEGFR-1 and VEGFR-2 have seven 44 
extracellular immunoglobulin (Ig)-like domains, which consist of a tetramer of two light chains and 45 
two heavy chains linked by disulphide bonds, a single transmembrane region, and an intracellular 46 
tyrosine kinase sequence interrupted by a kinase insert domain [3]. VEGF-A binds to the extracellular 47 
domain and the kinase-insert domain acts as a binding site for intracellular proteins to carry out 48 
specific signaling cascades in response to ligand binding. 49 
 50 
VEGFR-1 signaling 51 
VEGFR-1 was the first receptor tyrosine kinase for VEGF-A to be identified in COS cells [4] and has 52 
since been reported to be widely expressed on many cell types; however, it has very poor tyrosine 53 
kinase activity and is not required for endothelial cell function [5]. VEGFR-1 binds VEGF-A with 54 
high affinity but there is conflicting evidence for the role of VEGFR-1 as it appears to signal 55 
differently depending on the cell type and stage of development [5]. VEGFR-1 gene expression is 56 
regulated by hypoxia in human umblical endothelial cells; the VEGFR-1 promoter contains a binding 57 
site for hypoxia inducible factor (HIF)-1α [6]. Relatively little is known about the function of 58 
VEGFR-1. Constitutive knock-out (KO) of VEGFR-1 results in embryonic lethality between 59 
embryonic days 8.5 and 9 [7]. This was later found to be the result of increased endothelial cell 60 
outgrowth and angioblast commitment, which prevented proper organization of the vascular network 61 
[8]. Previous reports have labelled VEGFR-1 as a decoy receptor, decreasing the amount of VEGF-62 
A readily available to bind to and phosphorylate VEGFR-2 [9]. Further evidence for this is that 63 
deletion of just the intracellular kinase domain for VEGFR-1 resulted in normal vascular development 64 
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in mice [9]. Therefore, VEGFR-1 is hypothesized to sequester VEGF-A, preventing it from binding 65 
to its functional receptor, VEGFR-2. 66 
 67 
Function of sVEGFR-1 68 
The VEGFR-1 pre-mRNA can be alternatively spliced to produce the full-length membrane-spanning 69 
receptor described above, or the truncated soluble VEGFR-1 (sVEGFR-1), which includes the seven 70 
N-terminal immunoglobulin-like extracellular domains but not the transmembrane spanning or 71 
intracellular kinase domains, thus has a specific 31-amino acid c-terminus [1]. Full-length VEGFR-1 72 
mRNA consists of 30 exons, whereas sVEGFR-1 only contains the first 13-14 exons due to intron 73 
retention and usage of an alternative polyadenylation signal and stop codon (isoforms detailed below). 74 
sVEGFR-1 is suggested to form non-signaling complexes with VEGFR-2, thus functioning as a 75 
modulator of VEGF-A signaling [10]. Like full length VEGFR-1, sVEGFR-1 has also been shown to 76 
act as a decoy receptor; VEGFR-1 KO mice die from vasuclar overgrowth due to increased singlaing 77 
of VEGF-A through VEGFR-2; however, the administration of sVEGFR-1 to VEGFR-1 KO mice 78 
partially rescues this phenotype as it reduces the levels of VEGFR-2 phosphorylation [11]. 79 
There are currently five known VEGFR-1 protein coding isoforms (reviewed in [12]) (Figure 1A). 80 
Isoform 1 is denoted by the full-length VEGFR-1. Isoform 2 is termed sVEGFR-1, which comprises 81 
the 656 N-terminal residues followed by a specific 30 amino acid C-terminus and appears to have 82 
ubiquitous expression throughout most tissues [12]. Isoform 3 is a second soluble form generated by 83 
alternative splicing downstream of exon 14, termed sVEGFR-1_i14, which has been predmoniantly 84 
detecte din the testes and brain [12]. Isoforms 4 and 5 result from the use of a new terminal exon, 85 
termed exon 15a and 15b, which is derived from an intronic sequence. These isoforms have been 86 
found to be highly expressed in the placenta [12]. Alternative splicing of VEGFR-1 involves cis-87 
regulatory elements in the VEGFR-1 pre-mRNA within intron 13 [13]. Hypoxia is reported to 88 
increase the expression of transmembrane VEGFR-1 [6]; however, the effect of hypoxia on sVEGFR-89 
1 expression is not so clear. In endothelial cells, hypoxia was shown to downregulate the expression 90 
of sVEGFR-1, which was not directly attributable to HIF-1α [14]. In contrast, exposure of 91 
macrophages/monocytes to granulocyte-macrophage colony-stimulating factor (GM-CSF) under 92 
hypoxic conditions results in HIF-2α-dependent changes in sVEGFR-1 expression [15]. In 93 
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cytotrophoblasts, where the sVEGFR-1_i14 isoform is most commonly expressed, hypoxia increases 94 
both sVEGFR-1_i14 and sVEGFR-1 mRNA, which is proposed to be through HIF-1α [16]. 95 
Furthermore, sVEGFR-1_i14 secretion was shown to increase under hypoxic conditions through 96 
activation of the growth arrest and DNA damage-inducible 45a (Gadd45a) factor and p38 97 
phosphorylation [17]. Several drugs and protein factors have been shown to modulate sVEGFR-1 98 
expression, including Jumonji domain-containing protein 6, which interacts with the splice factor 99 
U2AF65 resulting in augmented levels of sVEGFR-1 in hypoxic conditions [18]. In addition, hnRNP 100 
D and arginine methylation have also been reported to play important roles in the regulation of 101 
sVEGFR-1 mRNA alternative polyadenylation [19]. Interestingly, VEGF-A can increase the 102 
expression of sVEGFR-1 through VEGFR-2-dependent activation of protein kinase C [20]. 103 
  104 
Figure 1. Alternative splice variants of VEGFR-1 and VEGFR-2. A) Alternative splicing gives 105 
rise to five known splice variants of VEGFR-1; full length VEGFR-1, intron 13 retention (sVEGFR-106 
1_i13), intron 14 retention (sVEGFR-1_i14), terminal exon 15a (sVEGFR-1_e15a), and terminal 107 
exon 15b (sVEGFR-1_e15b). The soluble isoforms only contain the extracellular (EC) domain and 108 
are missing the transmembrane (TM) and kinase (K1 and K2) domains. B) Alternative splicing gives 109 
rise to two known splice variants of VEGFR-2; full length VEGFR-2 and sVEGFR-2, which results 110 
from intron 13 retention. The sVEGFR-2 only contains the EC domain. 111 
 112 
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VEGFR-2 signaling 113 
VEGFR-2 is the main signaling receptor for VEGF-A. It is primarily located on endothelial cells and 114 
is essential for endothelial cell biology both during development and during physiological and 115 
pathological processes in adults. Like VEGFR-1, all VEGF-A isoforms contain residues that enable 116 
them to bind to VEGFR-2 and all bind with the same affinity. However, the affinity of VEGF-A for 117 
VEGFR-2 is 10-fold lower than that for VEGFR-1 [21,22]. A constitutive KO of VEGFR-2 results 118 
in embryonic lethality on day 8.5-9.5; mice lack mature endothelial and hematopoietic cells [23]. This 119 
is similar to the phenotype observed in VEGF-A KO mice [24]. Therefore, unlike VEGFR-1, 120 
VEGFR-2 signaling is crucial for vascular development. 121 
Proteolytic hydrolysis of membrane-bound VEGFR-2 results in the generation of soluble VEGFR-2 122 
(sVEGFR-2) [12]. sVEGFR-2 is proposed to function as an inhibitor of angiogenesis by binding to 123 
and sequestering VEGF-A, blocking canonical VEGF-A-VEGFR-2 signaling [25,26]. A further 124 
sVEGFR-2 isoform generated by intron 13 retention has been described; as with VEGFR-1, retention 125 
of intron 13 yields a truncated transcript whose protein variant lacks the transmembrane and 126 
intracellular kinase domain of full length VEGFR-2 [27] (Figure 1B). This splice variant is reported 127 
to play a role in lymphangiogenesis by blocking VEGF-C [27]. Little is known regarding the 128 
mechanisms controlling this alternative splicing event. 129 
 130 
VEGF-A Splice Variants 131 
The human VEGF-A pre-mRNA consists of eight exons and seven introns. Alternative splicing of 132 
the VEGF-A pre-mRNA gives rise to a family of isoforms with a differing number of amino acids 133 
due to the exclusion/inclusion of various exons (e.g., VEGF-A121, VEGF-A165, VEGF-A189, and 134 
VEGF-A206, collectively known as VEGF-Axxxa where xxx denotes the number of amino acids) 135 
(Figure 2). Such isoforms are widely known to be pro-angiogenic, pro-permeability factors. In 136 
addition, the selection of an alternative 3’ splice site, known as the distal splice site, in exon 8 of the 137 
VEGF-A pre-mRNA results in a new family of VEGF-A isoforms, termed VEGF-Axxxb [28]. The 138 
resulting VEGF-Axxxb proteins differ in the C-terminal sequence by only six amino acids, resulting 139 
in radically different functional properties (Figure 2). In comparison to VEGF-Axxx, VEGF-Axxxb 140 
isoforms are collectively anti-angiogenic and reduce vessel permeability (anti-permeability). Sixteen 141 
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isoforms of VEGF-A have been identified, including an additional isoform, VEGF-Ax, which arises 142 
from trasnaltional readthrough of the VEGF-A transcript beyond the canonical stop codon 143 
(programmed translational read-through) [29]. 144 
  145 
Figure   2.   Alternative   splicing   of   VEGF-­‐‑A.   The   VEGF-­‐‑A   pre-­‐‑mRNA   is   comprised   of   8   exons.  146 
Inclusion/exclusion  of  exons  6a,  6b,  7a,  and  7b  gives  rise  to  VEGF-­‐‑A  isoforms  with  differing  numbers  147 
of   amino   acids.   The   use   of   an   alternative   3’   splice   site   in   exon   8   results   in   a   differing   c-­‐‑terminal  148 
sequence   of   amino   acids   (VEGF-­‐‑Axxxb   isoforms).   The   VEGF-­‐‑Axxxa   family   of   isoforms   have   pro-­‐‑149 
angiogenic,  pro-­‐‑permeability  properties  whereas   the  VEGF-­‐‑Axxxb  isoforms  are  anti-­‐‑angiogenic  and  150 
anti-­‐‑permeability.  Figure  adapted  from  Stevens  et  al.  2018.  151 
 VEGF-A splicing is predominantly regulated by a group of RNA binding proteins known as 152 
serine/arginine (SR) proteins. SRSF1, SRSF2, SRSF5, and SRSF6 have all been reported to play a 153 
role in VEGF-A alternative splicing [30]. Upon phosphorylation of multiple serine/arginine and 154 
proline/serine repeats, SR proteins are translocated from the cytoplasm to the nucleus where they bind 155 
to exonic sequence enhancers within the VEGF-A pre-mRNA, resulting in the splicing out of an exon 156 
[31]. The inclusion/exclusion of certain exons result in the different isoform properties of each VEGF-157 
A protein. Exons 1-5 are constitutive exons; they encode a single sequence (exons 1/2), a 158 
glycosylation site (Asp74), a potential plasmin cleavage site (Arg110 and Ala111), as well as VEGFR 159 
binding residues [32,33]. Whereas exons 1-5 are present in all isoforms of VEGF-A, exons 6 and 7 160 
are alternatively spliced. Heparin sulfate (HS) glycoproteins are present in the extracellular matrix 161 
(ECM) and can interact with both VEGF-A and VEGFRs, thus they are suggested to regulate the 162 
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bioavailability of VEGF-A. Residues in exon 6a and 7 of VEGF-A are responsible for the interaction 163 
with HS [34]. VEGF-A145, VEGF-A189, and VEGF-A206 all contain exon 6a and 7 resulting in a high 164 
affinity for HS; this results in these longer isoforms being tethered to the ECM. On the other hand, 165 
VEGF-A111 and VEGF-A121 lack exon 6 and 7, so they are unable to bind HS making them freely 166 
diffusible in the ECM and more bioavailable [35]. The most dominant isoform is VEGF-A165, which 167 
contains exon 7 but not 6. Therefore, VEGF-A165 has an intermediate bioavailability as approximately 168 
50% remains cell- or ECM-bound [36]. 169 
 Regarding exon 8 of the VEGF-A gene, selection of either the proximal or distal splice site has 170 
been reported to be dependent on the type of external stimulus; proximal splice site selection is 171 
promoted by insulin like growth factor (IGF1) and tumor necrosis factor alpha (TNFα), whereas distal 172 
splice site selection is promoted by tumor growth factor beta 1 (TGF-B1) [37]. A widely reported 173 
example of exon 8 splicing regulation involves serine/threonine-protien kinase 1 (SRPK1) and CDC-174 
like kinase 1 (Clk-1). SRPK1 activation has been shown to phosphorylate SRSF1, resulting in 175 
proximal splice site selection and the translation of VEGF-Axxxa proteins [38]. On the other hand, 176 
Clk-1 signaling results in the phosphorylation of SRSF6, with the distal splice site being subsequently 177 
selected and VEGF-Axxxb proteins translated [37]. Other reported regulators of VEGF-A exon 8 178 
splicing are E2F1 and SRSF2, which were both shown to increase the VEGF-Axxxb/VEGF-Axxxa ratio 179 
[39]. 180 
 181 
VEGFR Signaling 182 
Role of VEGFR-1 signlaing and sVEGFR-1 isoforms 183 
As mentioned previously, the role of VEGFR-1 in vasculogenesis and angiogenesis has been ascribed 184 
to VEGF-A binding, thus regulating the amount of VEGF-A available for vascular development. 185 
VEGFR-1 is widely expressed but has poor kinase activity and is not required for endothelial cell 186 
function. Further evidence for this hypothesis arose from mice with a homozygous deletion of the 187 
VEGFR-1 tyrosine kinase domain developing healthy vasculature [9]. Therefore, the primary role of 188 
VEGFR-1 in embryonic angiogenesis is restricted to its extracellular region and is independent of its 189 
tyrosine kinase activity. As sVEGFR-1 contains the extracellular domain, it also acts as a decoy 190 
receptor [40]. sVEGFR-1 is also proposed form non-signaling complexes with VEGFR-2 [10]. 191 
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 A study using VEGFR-1 KO embryonic stem cells showed that sVEGFR-1 is important for the 192 
modulation of endothelial cell migration and vascular sprouting during development [41]. During 193 
vessel morphogenesis, endothelial cells are suggested to form a VEGF-A gradient via the interaction 194 
of VEGF-A with sVEGFR-1, resulting in sequestration of VEGF-A and local inactivation of VEGFR-195 
2 signaling [42]. Therefore, sVEGFR-1 is proposed to act as a guidance molecule during vessel 196 
sprouting, i.e. inactivating VEGF-A either side of the sprout to provide a VEGF-A-rich corridor for 197 
the emerging vessel [43]. sVEGFR-1 present in the ECM is also reported to play a role in α5β1 198 
integrin signaling regarding the cell adhesion pathway [44]; however, these signaling pathways are 199 
not related to VEGF-A and are beyond the scope of this review. 200 
 Recent studies have highlighted that VEGF-B and PIGF are able to signal through VEGFR-1, 201 
eliciting a pro-angiogenic effect independent of VEGF-A [45,46]. In addition, increased levels of 202 
sVEGFR-1 have been observed in vascular pathologies [45], indicating that VEGFR-1 may act as 203 
more than a decoy receptor/VEGFR-2 inhibitor. 204 
The role of sVEGFR-1 in tumor development and progression has been widely reported. The 205 
expression of sVEGFR-1 has been found to be increased in many types of cancer, including 206 
glioblastoma, melanoma, breast, hepatocellular, lung, leukemia, colorectal, renal, and head and neck 207 
[47-55]. Increased circulating sVEGFR-1 is often correlated with poor prognosis; however, the 208 
balance between VEGF-A and sVEGFR-1 may be more important when considering the clinical 209 
outcome. For example, increased sVEGFR-1 and VEGF-A are correlated with poor prognosis in lung 210 
cancer patients [51]. On the other hand, increased VEGF-A combined with low levels of sVEGFR-1 211 
are associated with a poor prognosis in breast cancer [56]. In addition to being a marker for tumor 212 
progression, sVEGFR-1 has also been shown to serve as a biomarker for tumor response to therapy. 213 
Using the example of bevacizumab, increased plasma levels of sVEGFR1 was reported to be inversely 214 
correlated with treatment response in breast cancer [57]. However, this appears to be dependent on 215 
the type of cancer as the sVEGFR-1 expression level was found to be decreased upon treatment of 216 
metastatic colorectal cancer [58].  217 
 Excess circulating soluble isoforms of VEGFR-1 have been shown to contribute to the 218 
pathogenesis of pre-eclampsia in pregnant women [59,60]. The sVEGFR-1_i14 isoform is presumed 219 
to be a major contributor to this condition because it is selectively expressed by placental 220 
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cytotrophoblasts; the increased sequestration of platelet-derived growth factor (PIGF) and VEGF-A 221 
by excess sVEGFR-1_i14 results in endothelial dysfunction and altered neutrophil activation and 222 
migration, ultimately causing hypertension, proteinuria, and glomerular endotheliosis in patients 223 
[60,61]. Indeed, increased levels of circulating sVEGFR-1_i14 is used as a biomarker for the 224 
development of pre-eclampsia [62].  225 
As described above in pregnant women with pre-eclampsia, increased circulating levels of 226 
sVEGFR-1 is linked to endothelial dysfunction in the glomeruli of the kidney. VEGF-A is secreted 227 
by the glomerular epithelial cells (podocytes) to signal to VEGFR-2 on the glomerular endothelial 228 
cells, a process that is tightly regulated to maintain proper functioning of the glomerular filtration 229 
barrier. Plasma levels of sVEGFR-1 are higher in patients with chronic kidney disease (CKD), which 230 
are correlated with cardiovascular disease [63,64]. On the other hand, inducible over-expression of 231 
podocyte sVEGFR-1 has been shown to be therapeutic in a model of diabetic nephropathy where 232 
excess VEGF-A expression is observed [65]. In addition, sVEGFR-1 has been reported to bind to 233 
lipid microdomains in podocytes, which can alter cell morphology and the function of the glomerular 234 
filtration barrier [66]. 235 
sVEGFR-1 has also been shown to play a role in ocular pathologies through the inhibition of 236 
VEGF-A, including the preservation of cornea avascularity [67]. In addition, reduced levels of 237 
sVEGFR-1 where observed in patients with age-related macular degeneration [68]. Regarding 238 
inflammation, increased levels of sVEGFR-1 in the blood is indicated to act as a potential new 239 
biomarker of sepsis [69], and a predictor of endothelial dysfunction/activation of coagulation in acute 240 
pancreatitis [70]. 241 
On the other hand, in mouse xenograft models of melanoma, lung cancer, fibrosarcoma, and 242 
glioblastoma, exogenous administration of sVEGFR-1 (either transfection, recombinant protein, or 243 
adenovirus infection) inhibited tumor growth and neoangiogenesis, increasing the survival rate [71-244 
74]. 245 
 246 
VEGF-Axxxb activation of VEGFR-1 247 
Information on VEGFR-1 activation and signaling is sparse; however, a recent study has shown that 248 
VEGF-A165b inhibits VEGFR-1 signaling in ischemic muscle in mice, and that VEGF-A165b 249 
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inhibition induces activation of VEGFR-1 [75]. Furthermore, in vitro studies showed that VEGF-250 
A165b failed to induce the activation of VEGFR-1-Y1333, reducing VEGFR-1-STAT3 signaling [75].  251 
 252 
Mehcanisms of VEGFR-2 signaling 253 
As mentioned above, all VEGF-A isoforms can bind to VEGFR-2 with similar affinity; however, 254 
different isoforms result in different activation and signaling outcomes [32] (Figure 3). Upon binding 255 
of VEGF-A to its orthosteric ligand binding site, VEGFR-2 undergoes dimerization and a 256 
conformational twist in the extracellular region results in the rotation of transmembrane helices 257 
[76,77]. Both VEGF-A165 and VEGF-A165b have been shown to result in VEGFR-2 dimerization [77]. 258 
Conformational changes in the intracellular domain of VEGFR-2 follows; ATP binds to the flexible 259 
N-lobe cleft facilitating the intrinsic kinase activity of the receptor and phosphorylation of the tyrosine 260 
residues in the C-lobe [78]. Upon phosphorylation of these tyrosine residues, certain cytoplasmic 261 
proteins bind and distinct signaling pathways are initiated, included those involved in cell survival, 262 
migration, proliferation, vasodilatation, and permeability (reviewed in [79]). The tyrosine residues 263 
include Y1054 and Y1059 in the activation loop, which are required for maximal kinase activity of 264 
VEGFR-2 [80]; Y951 in the kinase insert domain, which serves as a binding site for T cell-specific 265 
adapter molecule (TSAd) [81], and is vital for HUVEC migration in response to VEGF-A [82]; and 266 
Y1175 and Y1214 in the COOH-terminal tail. Y1175 phosphorylation mediates cell proliferation 267 
through binding of phospholipase C (PLC)-γ [83]. VEGFR-2 is dephosphorylated by protein 268 
phosphatase 1b (PTP1b) in the endoplasmic reticulum, which highlights the importance of 269 
spatiotemporal trafficking on the activation of VEGFR-2 [84,85]. 270 
Cells  2019,  8,  x  FOR  PEER  REVIEW   11   of   32  
 
  271 
Figure  3.  VEGF-­‐‑Axxxa  and  VEGF-­‐‑Axxxb  signaling  through  VEGFR  splice  variants  and  NRP1.  Both  272 
VEGF-­‐‑Axxxa   and   VEGF-­‐‑Axxxb   can   bind   and   dimerize   VEGFR-­‐‑2.   VEGF-­‐‑Axxxa   recruits   NRP1,   a   co-­‐‑273 
receptor  for  VEGFR-­‐‑2,  which  results  in  phosphorylation  of  the  tyrosine  kinase  domains  of  VEGFR-­‐‑2,  274 
producing  pro-­‐‑angiogenic  and  pro-­‐‑permeability  intracellular  signaling  cascades.  In  contrast,  VEGF-­‐‑275 
Axxxb  is  unable  to  recruit  NRP1,  resulting  in  weak,  transient  phosphorylation  of  VEGFR-­‐‑2  and  some  276 
pro-­‐‑survival  signaling  cascades.  Soluble  isoforms  of  NRP1,  as  well  as  sVEGFR-­‐‑2  and  sVEGFR-­‐‑1  lack  277 
transmembrane  domains  and  act  as  decoy  receptors,  sequestering  VEGF-­‐‑A.  278 
VEGFR-2 signaling in angiogenesis 279 
During sprouting angiogenesis, endothelial cells within existing vessels form an angiogenic sprout 280 
towards a chemotactic stimulus, such as VEGF-A. The angiogenic sprout is orientated with a leading 281 
tip cell and trailing stalk cells. The extent of sprouting in neighboring endothelial cells is regulated 282 
by delta-like ligand 4 and Notch via lateral inhibition [86]. Lumen formation occurs once two sprouts 283 
anastomose, and the new vessel is stabilized by smooth muscle cell and basement membrane 284 
deposition [87].  285 
 Cell proliferation is required for angiogenesis. VEGF-A activates VEGFR-2 and stimulates 286 
proliferation through the activation of RAS, which then activates RAF kinase to phosphorylate 287 
mitogen-activated protein kinases (MAPK/ERK) [88]. VEGFR-2 stimulates ERK activation via 288 
Y1175-dependent phosphorylation of PLC-γ, resulting in the subsequent activation of protein kinase 289 
C (PKC) [82]. Mutation of Y1175 or administration of and antibody specific to Y1175 decreased 290 
VEGF-A-dependent cell proliferation in vitro [89]. Furthermore, mutation of Y1175 in mice results 291 
in embryonic lethality on day 5-9 due to a lack of blood vessel formation [90].  292 
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 Endothelial cell migration is also essential for angiogenesis. One VEGFR-2 signaling pathway 293 
that has been implicated in endothelial cell migration is initiated via the phosphorylation of Y951, 294 
which allows for the binding of T cell specific adapter protein (TSAd) [81]. Both mutation of Y951 295 
and knock-down of TSAd are reported to inhibit VEGF-A-mediated actin reorganization, thus 296 
migration in cultured endothelial cells; however, proliferation remained unaffected [81]. Another 297 
example of a VEGFR-2 signaling pathway involves phosphorylation of Y1175 to induce focal 298 
adhesion kinase (FAK)-mediated endothelial cell migration [91]. 299 
 300 
VEGFR-2 signaling in cell survival 301 
VEGF-A activation of VEGFR-2 is associated with increased endothelial cell survival. VEGFR-2 302 
activates phosphoinositide 3-kinase (PI3K), which enables membrane recruitment and 303 
phosphorylation of protein kinase B (PKB/AKT) [92]. Activation of the cell survival factor AKT 304 
results in the phosphorylation of Bcl-2 associated death promoter (BAD), inhibiting the activity of 305 
pro-apoptotic factors such as Bcl-2 and caspase 9 [93]. 306 
 307 
VEGFR-2 signaling in permeability 308 
VEGF-A activation of VEGFR-2 induces extravasation of proteins and leukocytes in vivo [94]. This 309 
is suggested to occur through two mechanisms: the formation of transcellular endothelial pores and 310 
the transient opening of paracellular junctions [95]. However, the exact signaling mechanisms 311 
regulating these events are not yet clear. One suggested mechanism involves VEGF-A-dependent 312 
endothelial nitric oxide synthase (eNOS) activation through PLC-γ and AKT, resulting in the 313 
activation of the pro-permeability factor nitric oxide (NO) [96,97]. 314 
 315 
Role of sVEGFR-2 316 
The alternatively spliced sVEGFR-2 isoform has been reported to act as an endogenous VEGF-C 317 
antagonist, preventing it from binding to VEGFR-3 and consequently inhibiting lymphatic endothelial 318 
cell proliferation [27]. In addition, like sVEGFR-1, sVEGFR-2 is a natural circulating decoy receptor 319 
for VEGF, thus acting as a ligand trap [98]. 320 
 321 
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VEGF-A isoform specific activation of VEGFR-2 322 
The canonical VEGF-Axxxa isoforms are widely described as pro-angiogenic, pro-permeability factors 323 
as they activate the aforementioned signaling pathways via VEGFR-2 binding and dimerization. On 324 
the other hand, VEGF-Axxxb isoforms are anti-angiogenic and anti-permeability, which is due to their 325 
effect on VEGFR-2 activation. Like VEGF-Axxxa, VEGF-Axxxb is still able to bind and dimerize 326 
VEGFR-2, but whether they result in phosphorylation of the tyrosine residues in the intracellular 327 
domain is not clear. The six-amino acid frame shift that occurs when the distal splice site is selected 328 
in the VEGF-A pre-mRNA results in the replacement of a positively charged arginine residue with 329 
neutral aspartic acid and lysine, which are predicted to decrease VEGFR-2 activation [99]. In 330 
pulmonary arterial endothelial (PAE) cells, VEGF-A165b was shown to induce VEGFR-2 activation 331 
(Y1052, Y1057) compared to untreated controls, but not to the same extent as that induced by VEGF-332 
A165 [99]. Another report suggested that recombinant VEGF-A165b can induce Y1175 activation to 333 
almost the same extent as VEGF-A165 in HEK293-VR2 cells [100]. In addition, VEGF-A165b can 334 
induce VEGFR-2 Y1175 phosphorylation to the same extent as VEGF-A165 in endothelial cells [75].  335 
However, anti-VEGF-A165b treatment of HUVECs and cultured visceral adipose tissue resulted in 336 
increased Y951 phosphorylation [101,102], indicating that VEGF-A165b antagonized Y951 337 
phosphorylation. Furthermore, treatment of glomerular endothelial cells with VEGF-A165b did not 338 
result in any increases in the overall phosphorylated state of VEGFR-2 (immunoprecipitation of 339 
VEGFR-2 followed by immunoblotting with a phospho-tyrosine antibody) [103]. Taken together, 340 
these findings indicate that VEGF-A165b acts as a VEGFR-2 partial agonist/antagonist via the 341 
differential modulation of site-specific phosphorylation on VEGFR-2.  342 
 In some pathologies, VEGF-A165b expression has been shown to be down-regulated relative to 343 
VEGF-A165a. For example, in the late stages of human diabetic nephropathy when the kidney is not 344 
filtering properly, kidney VEGF-A165b levels are down-regulated relative to VEGF-A165a; however, 345 
during the early stages of diabetic nephropathy when the kidney is functioning well, the VEGF-A165b 346 
isoform is increased [104]. Therefore, VEGF-A165b may play a protective role in early nephropathy 347 
but when the expression is decreased, increased angiogenesis and permeability occur resulting in a 348 
worse phenotype. Indeed, several studies in mouse models have shown the VEGF-A165b isoform to 349 
have reno-protective effects regarding glomerular permeability [103-106]. These protective effects 350 
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are indicated to be due to VEGF-A165b decreasing the phosphorylation of VEGFR-2, which has been 351 
shown in glomerular endothelial cells [103]. Decreased levels of VEGF-A165b have also been 352 
observed in certain cancers, including colon cancer and renal cell carcinoma [28,107]. This reduction 353 
in VEGF-A165b is often accompanied by an increase in the pro-angiogenic VEGF-A165a, which 354 
contributes to angiogenesis within the tumor. Administration of VEGF-A165b, or manipulation of 355 
VEGF-A splicing to promote VEGF-A165b expression (such as with SRPK1 inhibitors), has been 356 
shown to be therapeutic in many tumor models through inhibition of VEGF-Axxxa mediated 357 
angiogenesis [108,109]. On the other hand, VEGF-A165b has also been shown to promote lung tumor 358 
progression and specific knock-down of just the VEGF-A165b isoform reduced tumor growth in lung 359 
cancer cells [110]. Thus, the role of VEGF-A165b signaling may depend on the tissue it is expressed 360 
in. 361 
 VEGF-A121a is a shorter freely diffusible VEGF-A isoform. In contrast to VEGF-A165a, VEGF-362 
A121a has been shown to exhibit both partial and full agonist effects. On one hand, VEGF-A121a acts 363 
as a partial agonist of VEGFR-2 both in vivo and in vitro measurements of angiogenesis and signaling, 364 
respectively [5,99], as well as slowing HUVEC proliferation and reducing sprouting in comparison 365 
to VEGF-A165a [111,112]. In contrast, VEGF-A121a-induced angiogenic sprouting ex vivo has been 366 
reported to be both comparable [33] and reduced [113] in comparison to VEGF-A165a. Similar trends 367 
are seen regarding vascular permeability [114-116]. 368 
VEGF-A145a and VEGF-A189a are ECM-bound isoforms that also show reduced agonistic 369 
effects on VEGFR-2 signaling in comparison to VEGF-A165a. In HUVECs, VEGF-A145a had a 370 
reduced effect on proliferation and permeability relative to VEGF-A165a, but comparable effects on 371 
migration [114]. This was indicated to be due to reduced phosphorylation of VEGFR-2 in addition to 372 
reduced activation of AKT and ERK [114]. Similarly, VEGF-A189a resulted in decreased cell survival 373 
and proliferation in BAECs, but comparable effects to VEGF-A165a on migration [117,118].  374 
 375 
VEGFR Signaling Complexes 376 
VEGFR heterodimerization 377 
Computational modeling has predicted VEGFR-1/2 heterodimers to comprise 10-50% of signaling 378 
VEGFR complexes, which are favored over VEGFR-1 homodimers when the VEGFR-2 abundance 379 
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is higher [119]. There is evidence that suggest that VEGF-A stimulation of VEGFR-2 homodimers, 380 
VEGFR-1 homodimers, and VEGFR-1/2 heterodimers results in different efficacies of signal 381 
transduction; the pattern of Ca2+ flux was found to be unique for each type of receptor dimer in 382 
porcine aortic endothelial cells [120]. VEGF-A, VEGF-C, and VEGF-D have also been shown to 383 
induce the heterodimerization of VEGFR-2/3, which is required for certain ligand-dependent cellular 384 
responses mediated by VEGF-C and VEGF-D [121]. 385 
 386 
Roles of neuropilins NRP1 and NRP2 387 
Neuropilins can function as coreceptors with VEGFR-1 and VEGFR-2. There are two homologs of 388 
NRP, NRP1 and NRP2, which consist of a single transmembrane spanning domain with a small 389 
cytoplasmic domain lacking intrinsic catalytic function [122]. NRP1 was firstly suggested to bind in 390 
exon 7 of VEGF-A, which is present in isoforms such as VEGF-A165, forming a ternary complex with 391 
VEGFR-2 [112], thus primarily acting as a co-receptor for VEGFR-2. More recent studies have 392 
implicated the exon 8a-encoded arginine residue in the binding of VEGF-A to the b1 domain of NRP1 393 
[123]. Binding of VEGF-A to NRP1 enhances VEGF-A signaling in endothelial cells with respect to 394 
migration and survival [124-126]. Furthermore, NRP1 is reported to be essential for VEGF-A-395 
induced vessel sprouting and branching in angiogenesis [127]. NRP1 has also been shown to be 396 
associated with the adapter Synectin (GIPC), which is associated with the intracellular trafficking of 397 
VEGFR-2 [125]. In contrast, NRP2 acts as a co-receptor for VEGFR-3 and is therefore not involved 398 
with VEGF-A signal transduction [128]. In mice, both overexpression and disruption of NRP1 results 399 
in embryonic lethality on E12.5-13.5 due to vascular abnormalities [129]. Furthermore, siRNA [113] 400 
or antibody [112] blocking of NRP1 led to a decrease in VEGF-A165a-induced phosphorylation of 401 
VEGFR-2 in vitro. 402 
 In contrast to VEGF-A165, VEGF-A189, and VEGF-A145, fluorescent real-time ligand binding 403 
assays revealed that VEGF-A165b and VEGF-Ax are unable to bind to NRP1 as they lack the exon 7-404 
8a-encded residues [130]. This provides further evidence for the lack of VEGFR-2 singling induced 405 
by the weak agonist VEGF-Axxxb isoforms. There is conflicting data regarding the binding of VEGF-406 
A121a to NRP1 as it lacks exon 7, with most studies suggesting that although VEGF-A121a can bind 407 
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NRP1, albeit at a lower affinity, it is unable to bridge the NRP1/VEGFR-2 complex (reviewed in 408 
[131]). 409 
 410 
NRP1 and NRP2 splice variants 411 
NRP1 exists as a full-length membrane-bound form in addition four soluble isoforms. Full-length 412 
NRP1 is comprised of 17 exons. On the other hand, two soluble splice variants, s12NRP1 and s11NRP1, 413 
are generated during pre-mRNA processing via intron read through in the NRP1 gene, resulting in 414 
proteins that lack transmembrane and cytoplasmic domains of full-length NRP1 [132,133]. 415 
Functionally, these soluble isoforms of NRP1 were reported to bind VEGF-A165, although not VEGF-416 
A121, thus inhibiting VEGF-A165-induced phosphorylation of VEGFR-2 in endothelial cells resulting 417 
in reduced tumor growth (anti-tumor properties) [133]. Therefore, s12NRP1 and s11NRP1 appear to 418 
act as VEGF-A165 antagonists. Two further soluble isoforms of NRP1 have also been described, 419 
sIIINRP and sIVNRP, which are proposed to have similar biological and biomechanical properties as 420 
s12NRP1 and s11NRP1 [134]. The sIIINRP1 isoform results from the deletion of exons 10 and 11, while 421 
exon 12 is still present, followed by retention of the beginning of intron 12 (28 bp). The sIVNRP1 422 
isoform is missing exon 11, also resulting in intron 12 retention [134]. Both sIIINRP and sIVNRP have 423 
been shown to be expressed in normal and cancerous tissues and are capable of binding VEGF-A165, 424 
indicating that these two isoforms are antagonists for NRP1-mediated cellular activities [134]. The 425 
final isoform of NRP1 is NRP∆E16, which results from the skipping of exon 16 and replacement with 426 
an “AAG” Arg triple; however, this isoform does not have a functional difference to full length NRP1 427 
[135]. 428 
 NRP2 can also exist as a membrane bound or soluble form. The membrane bound form of NRP2 429 
has two splice variants, NRP2a and NRP2b, which differ in the last 100 amino acids of the c-terminus. 430 
Therefore, these two splice variants are proposed to bind different proteins and govern different 431 
molecular pathways [136]. NRP2b has been reported to have a prometastatic role in non-small cell 432 
lung cancer, whereas NRP2a in promoting metastasis and therapy resistance [137]. However, further 433 
studies are needed to clarify the roles of each of these splice variants with respect to VEGF-A binding 434 
and signaling. 435 
 436 
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Regulation of Splicing as a Therapeutic Intervention 437 
Research into the VEGF-A-VEGFR signaling axis in disease has recently taken a new 438 
direction focused on manipulating the splicing of these genes as a potential therapeutic avenue. One 439 
example of this is the regulation of the VEGF-Axxxa/VEGF-Axxxb ratio. Small molecule inhibitors of 440 
SRPK1, known as SRPIN340 and SPHINX31, have been shown to upregulate the VEGF-Axxxb 441 
isoforms relative to VEGF-Axxxa, which had a therapeutic effect in animal models of retinopathy 442 
[138,139]. Furthermore, a natural blueberry extract as also been shown to increase VEGF-443 
A165b/VEGF-A164a in the kidney of diabetic mice, exerting a therapeutic effect through a decrease in 444 
kidney fibrosis and permeability [140]. Regarding the VEGFRs, exogenous administration of 445 
sVEGFR-1 (either transfection, recombinant protein, or adenovirus infection) was reported to inhibit 446 
tumor growth and neoangiogenesis, increasing the survival rate in mouse xenograft models of 447 
melanoma, lung cancer, fibrosarcoma, and glioblastoma [71-74]. Therefore, further research into the 448 
regulation of VEGFR splicing is warranted to explore the potential therapeutic benefits of switching 449 
VEGFR splicing. 450 
 451 
Conclusion 452 
The VEGF-A-VEGFR axis is critical in both physiological and pathological angiogenesis and vessel 453 
permeability. The disruption of the splicing of just one of the genes involved in the VEGF-A-VEGFR 454 
axis (VEGF-A, VEGFR-1, VEGFR-2) can result in changes to the entire signaling axis, such as the 455 
increase in VEGF-A165a relative to VEGF-A165b resulting in increased VEGFR-2 signaling and 456 
aberrant angiogenesis in cancer. Further research into understanding the mechanisms by which the 457 
splicing of VEGF-A/VEGFR-1/VEGFR-2 is regulated will help in the development of drugs aimed 458 
at manipulating splicing or inhibiting specific splice isoforms in a therapeutic manner. 459 
 460 
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